GlassScriptPhysician profile
Usama H Ghazi
NPI 1023073467
$2,303.26
in general payments reported to CMS, 2019-2025
32 companies · $506 in 2025
The $506 reported for 2025 was more than what 79% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $150 · 2021: $273 · 2022: $153 · 2023: $544 · 2024: $482 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.91 | 2021-2025 | |
| Spr Therapeutics, INC | $273.52 | 2022-2025 | Sprint Pns System |
| Saluda Medical Americas, INC. | $213.35 | 2024-2025 | Evoke |
| International Rehabilitative Sciences, INC | $212.26 | 2024-2025 | Rs 4i Plus Sequential Stimulator |
| Allergan, INC. | $140.93 | 2019-2021 | |
| Boston Scientific Corporation | $133.47 | 2023-2025 | Wavewriter Alpha Prime 16, Intracept |
| Scilex Pharmaceuticals INC. | $101.17 | 2020-2025 | Ztlido |
| Abbott Laboratories | $97.33 | 2023-2024 | Proclaim, Eterna |
| Amgen INC. | $92.71 | 2019-2021 | |
| Lundbeck LLC | $88.85 | 2020-2025 | Vyepti |
| Arbor Pharmaceuticals, INC. | $68.09 | 2019-2021 | |
| Pfizer INC. | $65.08 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $51.03 | 2019-2025 | Belbuca |
| Bioventus LLC | $46.89 | 2023 | Stimrouter Implantable Kit |
| Assertio Therapeutics, INC. | $44.16 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.52 | 2019-2020 | |
| Lilly USA, LLC | $36.39 | 2020-2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $33.62 | 2022 | |
| Supernus Pharmaceuticals, INC. | $26.74 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $22.63 | 2020 | |
| Impel Pharmaceuticals INC. | $21.75 | 2022 | |
| Painteq LLC | $21.54 | 2024 | Painteq |
| Eisai INC. | $20.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.46 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $18.06 | 2019 | |
| Si-Bone, INC. | $17.78 | 2025 | |
| Ibsa Pharma INC. | $15.43 | 2021 | |
| Medtronic, INC. | $14.44 | 2022 | |
| Curonix LLC | $14.43 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biodelivery Sciences International, INC. | $14.10 | 2019 | |
| Nalu Medical, INC. | $13.99 | 2021 | |
| Stimwave Technologies Incorporated | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usama Ghazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.